🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11364235

    Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

    Actinium Phamaceuticals, Inc. · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11357795

    Combination immunotherapies for treatment of cancer

    PrimeVax Immuno-Oncology · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11357841

    Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11357742

    Methods for treating cancer

    X4 Pharmaceuticals, Inc. · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11357842

    PD-L1 targeting DNA vaccine for cancer immunotherapy

    Vaximm AG · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11351197

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11351199

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11352395

    Anticancer peptides

    IDP DISCOVERY PHARMA, S.L. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11351185

    Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11351198

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11344581

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11345733

    Colon and pancreas cancer specific antigens and antibodies

    PRECISION BIOLOGICS, INC. · Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11344580

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11344579

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11338026

    Identification of immunologically protective neo-epitopes for the treatment of cancers

    UNIVERSITY OF CONNECTICUT · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11338029

    Cancer vaccines targeting PRAME and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11339213

    Methods and compositions for treatment of cancer

    MEREO BIOPHARMA 5, INC. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11338003

    Methods of treating bladder cancer with an oncolytic virus

    CG ONCOLOGY, INC. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11337969

    Methods for treating cancer

    X4 Pharmaceuticals, Inc. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11337998

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11338028

    Cancer vaccines targeting LEMD1 and uses thereof

    Inovio Pharmaceuticals, Inc. · Granted Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11324822

    Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

    Syndax Pharmaceuticals, Inc. · Granted Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11311485

    Self-assembled particles for targeted delivery of immunomodulators to treat autoimmunity and cancer

    Northwestern University · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11311578

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11311517

    Combination of small molecule CD-47 inhibitors with other anti-cancer agents

    Aurigene Discovery Technologies Limited · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11312787

    Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

    The Regents of the University of California · Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11304980

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11304979

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11304988

    Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (KLC1C)

    Northwestern University · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11304950

    Methods for treating testicular and ovarian adrenal rest tumors

    SPRUCE BIOSCIENCES, INC. · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11298378

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11291687

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11293009

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Iovance Biotherapeutics, Inc. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11291663

    Methods of treating cancer with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11292842

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11285194

    Combination immunotherapy approach for treatment of cancer

    Calidi Biotherapeutics, Inc. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11285154

    Methods and compositions for treating cancer

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11279934

    Methods for treating cancer using nucleic acids targeting MDM2 or MYCN

    Phio Pharmaceuticals Corp. · Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11279768

    Anti-cancer antibodies, combination therapies, and uses thereof

    PRECISION BIOLOGICS, INC. · Granted Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11273181

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11273180

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11266726

    Compositions and methods for the treatment of HER2-expressing solid tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11266746

    Therapeutic antitumor combination of a TLR4 ligand with other treatments

    The United Slates of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11266694

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11260058

    Compositions and method of treating cancer

    The Regents of the University of California · Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11261237

    Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11253522

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11254752

    Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.